The maker of Ozempic is halving the price of its weight-loss jabs in the US after Donald Trump demanded cheaper drugs for Americans.

This week, medication savings platform GoodRx announced a partnership with Novo Nordisk – the company behind Ozempic and Wegovy – to offer the drugs at nearly half price for self-paying patients.

Price hikes are 'kick in the teeth' for patients who will either have to swallow 170 per cent price increase, or switch to 'almost as good' competitor

Novo Nordisk announced Monday that people who use Ozempic can now get it for half the price if you pay in cash.

Many Mounjaro users are looking into alternative medications following news of a 170 percent price increase in the UK

The drug is available as a weight-loss medication under the brand name Wegovy and will now also be sold directly to diabetes patients

GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of Ozempic (semaglutide) and Wegovy (semaglutide) pens are available to eligible self-paying patients for $499-per-month through GoodRx,